New normal declared and staffed: management says the company's recent level of business has become its new baseline, and
The model's full reasoning — Q3 2018 call → NOThe user asks me to determine whether management conveys that the level of business has become the new normal, with both (1) a higher level already real and framed as the new baseline, and (2) the company operating to that level now. Let me analyze the transcript carefully. Key points from the call: - Q3 2018 results: total revenue growth ~14% YoY to $248.7M, non-GAAP net income $11.6M - VIVITROL net sales +15% YoY to $79.9M, unit growth 18% - ARISTADA net sales +48% YoY to $36.1M - AMPYRA revenues higher than expected due to delayed generic entry - They raised full-year guidance by $30M due to AMPYRA upside Now, is there any indication that the current level of business is a "new normal" - that activity which would recently have been exceptional is now presented as ordinary? Looking at the transcript: - The AMPYRA revenue increase is explicitly attributed to delayed generic entry - this is a one-time/temporary condition. Jim Frates says "We expect revenues from AMPYRA and FAMPYRA in the fourth quarter to be approximately $20 million. Due to the recent launch of generic competition in the United States, we expect our AMPYRA revenues will be substantially lower during 2019." This is clearly a temporary spike, not a new normal. - VIVITROL and ARISTADA growth is described as ongoing, but there's no indication that this represents a step-change above what was recently usual. The growth rates (15%, 48%) are presented as normal quarterly results within the company's trajectory. - The company raised guidance, but this was specifically due to AMPYRA upside, which they explicitly say will unwind. Is there any language about "new baseline," "now routinely doing business of a kind it seldom did before," or similar? No. The management discusses growth but doesn't frame it as a step-change in the company's operating level. The AMPYRA upside is explicitly framed as temporary - "Due to the recent launch of generic competition in the United States, we expect our AMPYRA revenues will be substantially lower during 2019." This is the opposite of a new normal. For VIVITROL and ARISTADA, the growth is presented as ongoing business development, not as a step-change to a new operating level.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ECPG | Encore Capital Group, Inc. | Q1 2024 | 2024-05-08 | B |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
UAL · Q4 2022 → YESThe question is: Does management convey that the LEVEL OF BUSINESS THE COMPANY IS NOW DOING HAS BECOME ITS NEW NORMAL — that activity which would recently have been exceptional is now the company's cu...YES The transcript shows management framing the post-pandemic operating environment—higher margins, sustained demand recovery, capacity constraints, and investments in staffing/technology—as the new baseline for United's business. Scott Kirby explicitly states that structural changes have set the industry (and United) up for higher margins than pre-pandemic levels, with United achieving 9% adjusted pre-tax margin in H2 2022 ahead of schedule and expecting to hit it again in 2023. They describe current activity (e.g.
CRL · Q2 2022 → YESThe question is whether management conveys that the current level of business has become the new normal, meaning activity that would recently have been exceptional is now ordinary, and they're doing r...YES The transcript shows management framing the elevated activity in Safety Assessment (DSA segment) as the new baseline: backlog "well above the prior year level," "significantly above prior year levels," "unprecedented demand," "never seen this sort of commitment that far out with better pricing," and "large portion of 2023 revenue already booked.
DAL · Q2 2023 → YESThe question is: Does management convey that the LEVEL OF BUSINESS THE COMPANY IS NOW DOING HAS BECOME ITS NEW NORMAL — that activity which would recently have been exceptional is now the company's cu...YES The transcript shows management framing the current performance as the new baseline: record revenue and earnings, "highest quarterly earnings result in our history," "moves Delta beyond recovery and firmly on a great path forward," and executing ahead of the three-year plan with raised full-year guidance.